Prokidney

Prokidney Dividend Yield

Dividend Yield of Prokidney (PROK) as of Oct 16, 2026.

Dividend Yield

-

Last updated:

Dividend Yield of Prokidney is 2026 - . Dividend Yield of Prokidney was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prokidney Stock analysis

What does Prokidney do? Prokidney Corp, based in Winston-Salem, North Carolina, is a clinical-stage biotechnology company focused on developing cell therapy platforms for chronic kidney diseases. The company employs 231 people and is listed on the stock market since June 30, 2021. Its lead product, Renal Autologous Cell Therapy (REACT), uses a patient's own kidney cells to preserve kidney function in chronic kidney disease patients. REACT is currently in global Phase 3 trials and multiple Phase 2 trials for diabetic kidney disease. Prokidney is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prokidney stock

On Eulerpool you can find the complete historical development of Dividend Yield Prokidney since 2006 – with annual values, charts, and detailed analysis.

Dividend yield measures the annual dividend payment relative to the stock price. It shows the return an investor receives from dividends alone.

Dividend Yield's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Yield's Prokidney historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Prokidney

All Key Metrics — Prokidney